![](images/graphics/blank.gif)
Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves’ orbitopathy: A preliminary study
18
lượt xem 0
download
lượt xem 0
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
The study included 35 patients: 15 with GO, 10 with Graves' disease (GD) without GO and 10 controls. Patients with GO received methylprednisolone (MP) for 12 weeks. Concentrations of thyrotropin receptor antibodies (TSHRab), interleukin 17 (IL-17) and 23 (IL-23) were obtained before administering the first dose of MP, after 6 and 12 weeks of therapy, and 3 months after treatment cessation.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD